Navigation Links
Bioniche Revolving Credit Facility Maturity Date Amended
Date:3/2/2009

BELLEVILLE, ON, March 2 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that the Company has amended the maturity date of its existing secured revolving credit facility with Valens U.S. (formerly Laurus Master Funds).

On October 31, 2008, Bioniche and Valens agreed to a near-term extension of this facility, originally scheduled to mature on December 19, 2008. This extension was provided to the Company in order to allow it time to identify new banking partner(s), after Valens decided to withdraw its credit due to recent market conditions. The original revolving credit facility was established in 2005.

This amendment will replace the previously agreed maturity date of March 2, 2009 with an "on demand" status, with the expectation that the Company will meet its near-term corporate objectives. There are no fees or penalties resulting from this amendment.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2009. For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-loo
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Bioniche Responds to Australian Equine Influenza Outbreak
2. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
3. Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards
4. Bioniche Receives Comment from USDA on a Field Trial for E. coli O157:H7 Cattle Vaccine
5. Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial
6. Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Bioniche Reports Fiscal 2008 First Quarter
8. Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario
9. Bioniche Amends Terms of Convertible Debt with Laurus Master Funds
10. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
11. Bioniche Reports Fiscal 2008 Second Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... psychologists have made a brain-related discovery that could ... , This discovery opens up the possibility that ... a specific brain activity that the researchers have ... Journal of Neuroscience has just published ... an associate professor of psychology and his doctoral ...
(Date:4/17/2014)... presence of chronic inflammation in benign prostate tissue ... and this association was found even in those ... a study published in Cancer Epidemiology, Biomarkers ... Association for Cancer Research. , An analysis of ... the placebo arm of the Prostate Cancer Prevention ...
(Date:4/17/2014)... vaccine brands for children may not be the most ... factors when choosing vaccines, driving the market toward what ... new study by University of Illinois researchers. , "The ... numerous factors," says Sheldon H. Jacobson, a co-author of ... of mathematics at the U. of I. "In an ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2
... of awards in the 2007 Association TRENDS All-Media Contest, ... Society Magazine as well as the category won by ... honored at the Salute to Association Excellence event on ... the official publication of the Society for Biomolecular Sciences. ...
... the past two decades and is now second to back ... than men to suffer from persistent neck pain, in particular ... a computer keyboard. Previous studies have shown conflicting results as ... but there has not been enough high-quality research in this ...
... are looking for,that magic pill that will make us look and ... longer a pill, and nutrition trends of 2008 will,put you on ... all,the hype," said Dr. Clive R. Spray, a biochemist and leader ... can we improve the health of our family and ourselves?, ...
... are so many health,recommendations in the media these days that ... they can make for better,health in the year ahead. ISSA ... strong -- for their top,recommendations for the 10 best things ... ahead. Here are the results of that survey:, ...
... MCKINNEY, Texas, Jan. 4 Torchmark Corporation,(NYSE: ... two of its leading,insurance subsidiaries, United American Life ... from Delaware to Nebraska. Torchmark,plans to redomesticate other ... the premium tax rates in a number of ...
... DaVita Inc. (NYSE:,DVA) announced today that it and ... partnership to provide dialysis and vascular,access services, as ... the greater Phoenix area. The partnership will own ... to provide patients with,access to all available treatment ...
Cached Medicine News:Health News:Strength training of neck muscles relieves chronic pain 2Health News:Nutrition Trends of 2008 2Health News:Nutrition Trends of 2008 3Health News:Nutrition Trends of 2008 4Health News:International Sports Sciences Association's Ten Best Resolutions for Better Health in 2008 2
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... REDWOOD CITY, Calif., March 19, 2012 Ingenuity Systems, ... life science researchers, today announced that the Weill Cornell ... iReport for use in its sequencing core facility.  Variant ... the output of whole genome and exome sequencing experiments ...
... 19, 2012  Johnson & Johnson (NYSE: JNJ) will provide ... parties on Monday, March 26th at approximately 10:30 ... College of Cardiology (ACC) Annual Scientific Sessions in ... of the EINSTEIN-PE study in treating patients with ...
Cached Medicine Technology:Weill Cornell Medical College Selects Ingenuity® Variant Analysis™ and Ingenuity® iReport™ for Sequencing Core Facility 2
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
Alkaline phosphatase FS (IFCC). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of alkaline phosphatase activity in serum or plasma. Kinetic reaction. 405 nm wavelength. 830 U/L at 30C linearity. Single vial, dry powder reagent....
For the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum or plasma. For in vitro diagnostic use only....
Medicine Products: